ACCOUNTS - Final Accounts preparation


Caseware UK (AP4) 2020.0.247 2020.0.247 2020-12-312020-12-31trueThe members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.2019-12-20truefalseResearch and devlopment on biotechnology3 12373627 2019-12-19 12373627 2019-12-20 2020-12-31 12373627 2018-12-20 2019-12-19 12373627 2020-12-31 12373627 c:Director2 2019-12-20 2020-12-31 12373627 d:PatentsTrademarksLicencesConcessionsSimilar 2020-12-31 12373627 d:CurrentFinancialInstruments 2020-12-31 12373627 d:CurrentFinancialInstruments d:WithinOneYear 2020-12-31 12373627 d:ShareCapital 2020-12-31 12373627 d:SharePremium 2020-12-31 12373627 d:RetainedEarningsAccumulatedLosses 2020-12-31 12373627 c:OrdinaryShareClass1 2019-12-20 2020-12-31 12373627 c:OrdinaryShareClass1 2020-12-31 12373627 c:FRS102 2019-12-20 2020-12-31 12373627 c:Audited 2019-12-20 2020-12-31 12373627 c:FullAccounts 2019-12-20 2020-12-31 12373627 c:PrivateLimitedCompanyLtd 2019-12-20 2020-12-31 12373627 c:SmallCompaniesRegimeForAccounts 2019-12-20 2020-12-31 12373627 d:PatentsTrademarksLicencesConcessionsSimilar d:ExternallyAcquiredIntangibleAssets 2019-12-20 2020-12-31 xbrli:shares iso4217:GBP xbrli:pure

Registered number: 12373627










MARIPOSA THERAPEUTICS LIMITED










FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE PERIOD ENDED 31 DECEMBER 2020



 
MARIPOSA THERAPEUTICS LIMITED
REGISTERED NUMBER: 12373627

STATEMENT OF FINANCIAL POSITION
AS AT 31 DECEMBER 2020

2020
Note
£

Fixed assets
  

Intangible assets
 4 
2,000,000

  
2,000,000

Current assets
  

Debtors: amounts falling due within one year
 5 
18,628

Cash at bank and in hand
 6 
7,022

  
25,650

Creditors: amounts falling due within one year
 7 
(60,956)

Net current (liabilities)/assets
  
 
 
(35,306)

Total assets less current liabilities
  
1,964,694

  

Net assets
  
1,964,694


Capital and reserves
  

Called up share capital 
 8 
20,920

Share premium account
  
2,071,080

Profit and loss account
  
(127,306)

  
1,964,694


The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the statement of income and retained earnings in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf on 16 September 2021.




T C Hafner
Director

The notes on pages 2 to 5 form part of these financial statements.

Page 1

 
MARIPOSA THERAPEUTICS LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 DECEMBER 2020

1.Accounting policies

 
1.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Section 1A of Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006.

The preparation of financial statements in compliance with FRS 102 requires the use of certain critical accounting estimates. It also requires management to exercise judgment in applying the Company's accounting policies.

Management has considered the consequences of Covid-19 and other events and conditions, and it has determined that they do not create a material uncertainty that casts significant doubt upon the entities ability to continue as a going concern at the current time.

The following principal accounting policies have been applied:

 
1.2

Intangible assets

Intangible assets are initially recognised at cost. After recognition, under the cost model, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

At each reporting date the company assesses whether there is any indication of impairment. If such indication exists, the recoverable amount of the asset is determined which is the higher of its fair value less costs to sell and its value in use. An impairment loss is recognised where the carrying amount exceeds the recoverable amount.

All intangible assets are considered to have a finite useful life. If a reliable estimate of the useful life cannot be made, the useful life shall not exceed ten years.

 
1.3

Debtors

Short term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

 
1.4

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

 
1.5

Creditors

Short term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

Page 2

 
MARIPOSA THERAPEUTICS LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 DECEMBER 2020

1.Accounting policies (continued)

 
1.6

Financial instruments

The Company only enters into basic financial instrument transactions that result in the recognition of financial assets and liabilities like trade and other debtors and creditors, loans from banks and other third parties, loans to related parties and investments in ordinary shares.


2.


General information

The Company is a private company, limited by shares and registered in Wales.
Its registered number is: 12373627
The address of its registered office is:
Units G-H, Roseheyworth Business Park,
Abertillery,
Gwent,
NP13 1SX


3.


Employees

The average monthly number of employees, including directors, during the period was 3.


4.


Intangible assets



Patents

£



Cost


Additions
2,000,000



At 31 December 2020

2,000,000






Net book value



At 31 December 2020
2,000,000



Page 3

 
MARIPOSA THERAPEUTICS LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 DECEMBER 2020

5.


Debtors

2020
£


Other debtors
18,628

18,628



6.


Cash and cash equivalents

2020
£

Cash at bank and in hand
7,022

7,022



7.


Creditors: Amounts falling due within one year

2020
£

Trade creditors
1,092

Amounts owed to group undertakings
49,760

Accruals and deferred income
10,104

60,956



8.


Share capital

2020
£
Allotted, called up and fully paid


2,092,000 Ordinary shares of £0.01 each
20,920


During the period, the Company issued 2,092,000 Ordinary £0.01 shares for a total consideration of £2,092,000.


9.


Related party transactions

During the period the Company issued 2,000,000 Ordinary £0.01 to Neem Biotech Limited for consideration of the assignement of £2,000,000 intellectual property rights from the parent company.

Page 4

 
MARIPOSA THERAPEUTICS LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 DECEMBER 2020

10.


Controlling party

The immediate parent undertaking is Neem Biotech Limited, whose registered office is Units G-H, Roseheyworth Business Park, Abertillery, Blaenau Gwent, NP13 1SX.
The ultimate parent undertaking is CTL Familienstiftung, a company incorporated in Leichtenstein, who's registered office is Feldircher Strasse 15, 9494 Schaan, Leichtenstein.
The trustee and ultimate beneficial owner is Dr H Schwarzler.


11.


Auditors' information

The auditors' report on the financial statements for the period ended 31 December 2020 was unqualified.

The audit report was signed on 17 September 2021 by Martin Van Beek (Senior statutory auditor) on behalf of Ashleys (Hitchin) Limited.

 
Page 5